Insulin glargine use and short-term incidence of breast cancer — a four-year population-based observation

Rickard LjungNational Board of Health and Welfare, Stockholm, Sweden;Upper Gastrointestinal Research, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden;Equity and Health Policy, Department of Public Health Sciences, Karolinska Institutet, Stockholm, SwedenCorrespondence[email protected]

Mats TalbäckNational Board of Health and Welfare, Stockholm, Sweden

Bengt HaglundNational Board of Health and Welfare, Stockholm, Sweden

Junmei Miao JonassonDivision of Clinical Cancer Epidemiology, Department of Oncology, The Sahlgrenska Academy, Onkologiskt Centrum, Gothenburg, Sweden;Division of Clinical Cancer Epidemiology, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden;National Diabetes Register, Register Center, Västra Götaland Region, Sweden

Soffia GudbjörnsdòttirDiabetes Centre, Sahlgrenska University Hospital, Gothenburg, Sweden;Nordic School of Public Health, Gothenburg, Sweden;National Diabetes Register, Register Center, Västra Götaland Region, Sweden

Gunnar SteineckDivision of Clinical Cancer Epidemiology, Department of Oncology, The Sahlgrenska Academy, Onkologiskt Centrum, Gothenburg, Sweden

References

Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G. Insulin glargine use and short-term incidence of malignancies – a population-based follow-up study in Sweden. Diabetologia 2009;52:1745–54.
PubMed Web of Science ®Google Scholar
Ljung R, Talback M, Haglund B, Jonasson JM, Gudbjornsdottir S, Steineck G. Insulin glargine use and short-term incidence of malignancies – a three-year population-based observation. Acta Oncol 2011;50:685–93.
PubMed Web of Science ®Google Scholar
WHO Collaboration Centre for Drugs Statistics Methodology [Internet]. Oslo: WHOCC. [cited 2011 Aug 30]. Available from: http://www.whocc.no/atcddd/
Google Scholar
Suissa S, Azoulay L, Dell'aniello S, Evans M, Vora J, Pollak M. Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia Epub 2011 May 26.
Google Scholar
Mannucci E, Monami M, Balzi D, Cresci B, Melani C, Lamanna C, . Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2010;33:1997–2003.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Insulin glargine use and short-term incidence of breast cancer — a four-year population-based observation

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Insulin glargine use and short-term incidence of breast cancer — a four-year population-based observation

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date